ARID1A-Related Intellectual Disability — designated ARID1A neurodevelopmental disorder, ARID1A Coffin-Siris Syndrome Type 2, or BAF complex subunit disorder, a rare autosomal dominant (de novo) neurodevelopmental syndrome caused by heterozygous loss-of-function pathogenic variants in ARID1A (AT-rich interaction domain 1A gene, chromosome 1p36; ARID1A encodes the largest subunit of the canonical BAF chromatin remodeling complex — the ARID domain-containing subunit that targets the BAF complex to AT-rich regulatory sequences and anchors the complex to genomic regulatory regions during chromatin remodeling; ARID1A and its paralogue ARID1B [Coffin-Siris Syndrome Type 1] are mutually exclusive subunits of the same canonical BAF complex, with only one present in any given BAF complex assembly; ARID1A is ubiquitously expressed and functions both as a tumor suppressor in somatic cancers — somatic loss-of-function mutations in ARID1A are among the most common cancer driver alterations found in ovarian clear cell carcinoma, endometrial carcinoma, and gastric cancer — and as a neurodevelopmental gene whose germline heterozygous loss-of-function causes a syndrome overlapping with Coffin-Siris Syndrome Type 1; this dual role creates a unique clinical imperative where ARID1A germline pathogenic variant carriers require both the neurodevelopmental monitoring applicable to all Coffin-Siris Syndrome patients and cancer surveillance considerations distinct from ARID1B Coffin-Siris Syndrome that arise from ARID1A's tumor suppressor function); the clinical phenotype of ARID1A neurodevelopmental disorder includes intellectual disability (mild to moderate, similar in severity to ARID1B Coffin-Siris Syndrome), absent or hypoplastic fifth fingernail or toenail (a pathognomonic Coffin-Siris feature that may be subtle in ARID1A), behavioral features (autism spectrum traits, ADHD, and anxiety), coarse facial features, hypotonia in infancy, epilepsy in approximately 25% of affected individuals, and short stature — with the critical clinical distinction from ARID1B Coffin-Siris Syndrome being the cancer surveillance considerations that adult ARID1A pathogenic variant carriers require given ARID1A's established tumor suppressor role in gynecological and gastric cancers.
ARID1A neurodevelopmental disorder technology platforms — encompassing the molecular genetics laboratories where neurodevelopmental gene panels, exome sequencing, and genome sequencing characterize the causative ARID1A pathogenic variant and distinguish ARID1A Coffin-Siris Syndrome Type 2 from ARID1B Coffin-Siris Syndrome Type 1, other BAF complex subunit disorders (SMARCA4, SMARCB1, SMARCE1), and the clinical differential of intellectual disability with fifth nail hypoplasia; the special education and IEP coordination platforms managing the cognitive testing, adaptive behavior assessment, and multi-disciplinary educational team coordination for mild-to-moderate intellectual disability; the behavioral management platforms — ABA therapy records, autism support plan tools, ADHD management systems, anxiety treatment records — managing the behavioral features that require integrated behavioral and pharmacological management; the seizure diary and AED monitoring platforms managing epilepsy in the approximately 25% of affected individuals; the cancer surveillance coordination platforms — gynecological oncology scheduling tools, ovarian cancer screening systems, endometrial monitoring platforms, gastric cancer family history documentation tools — managing the adult cancer surveillance that distinguishes ARID1A from ARID1B Coffin-Siris Syndrome; and the fifth nail documentation, hearing monitoring, ophthalmology coordination, and growth monitoring platforms managing the multiple clinical surveillance streams of modern ARID1A care — must maintain availability and performance standards matched to the cancer surveillance urgency, behavioral management requirements, and AED monitoring demands of contemporary ARID1A neurodevelopmental disorder management. This guide explains why ARID1A care tech platforms need dedicated monitoring, what to monitor, and how to build a monitoring strategy matched to the cancer surveillance distinction and multi-domain behavioral management requirements of ARID1A Coffin-Siris Syndrome Type 2.
Why ARID1A Neurodevelopmental Disorder Tech Platforms Require Specialized Monitoring Attention
ARID1A neurodevelopmental disorder management is defined by several clinically urgent platform requirements: the cancer surveillance urgency — ARID1A's role as a tumor suppressor in ovarian clear cell carcinoma, endometrial carcinoma, and gastric cancer creates surveillance considerations for adult female ARID1A germline pathogenic variant carriers that are absent in ARID1B Coffin-Siris Syndrome and require cancer surveillance platform availability to coordinate gynecological oncology monitoring; the ARID1A versus ARID1B documentation urgency — the molecular subtype distinction between ARID1A Coffin-Siris Type 2 and ARID1B Coffin-Siris Type 1 must be clearly documented in every clinical platform because it determines the cancer surveillance protocol that applies in adulthood; the behavioral management urgency — autism spectrum traits, ADHD, and anxiety require integrated ABA therapy coordination, pharmacological management, and school accommodation documentation that depend on longitudinal behavioral platform availability; the AED monitoring urgency — the approximately 25% of affected individuals with epilepsy require seizure diary documentation, AED adherence monitoring, and seizure action plan access; the hearing monitoring urgency — hearing loss reported in some ARID1A individuals requires annual audiological assessment scheduling and result documentation; and the ophthalmological monitoring urgency — strabismus is common in ARID1A neurodevelopmental disorder and requires annual eye examination scheduling and treatment coordination.
Molecular genetic testing platforms establish ARID1A loss-of-function and distinguish Coffin-Siris Type 2 from Type 1. Neurodevelopmental gene panels and exome/genome sequencing identify ARID1A versus ARID1B variants — a distinction determining adult cancer surveillance requirements. Monitor at 1-minute intervals during laboratory hours.
Cancer surveillance coordination platforms manage adult gynecological and gastric monitoring. Ovarian and endometrial cancer screening scheduling, gastric cancer family history documentation, and gynecological oncology coordination require platform availability for adult ARID1A female variant carriers. Monitor at 1-minute intervals during clinical hours.
Behavioral management platforms coordinate ABA therapy, ADHD management, and anxiety treatment. Autism support plans, ADHD medication records, anxiety treatment documentation, and school accommodation records require longitudinal platform availability. Monitor at 1-minute intervals during clinical hours.
Seizure diary and AED monitoring platforms manage epilepsy in affected individuals. Seizure documentation, AED adherence records, and seizure action plans are required for the 25% of ARID1A individuals with epilepsy. Monitor at 1-minute intervals during clinical hours.
Special education and IEP coordination platforms support mild-to-moderate intellectual disability. Cognitive testing, adaptive behavior assessment, and IEP documentation require platform availability across the school years. Monitor at 1-minute intervals during clinical hours.
What to Monitor on an ARID1A Neurodevelopmental Disorder Tech Platform
Molecular Genetic Testing — ARID1A Pathogenic Variant and Subtype Documentation
Monitor neurodevelopmental gene panel and exome/genome sequencing records (ARID1A pathogenic variant identification — frameshift, nonsense, splice-site, or large deletion; ACMG variant classification; impact on ARID domain function and BAF complex targeting; confirmation that variant affects ARID1A and not ARID1B — subtype documentation is the single most important record for adult cancer surveillance triage; trio analysis confirming de novo origin; parental carrier testing; BAF complex differential exclusion — SMARCA4, SMARCB1, SMARCE1, ARID2 testing records where indicated; chromosomal microarray records for 1p36 deletion encompassing ARID1A), genetic counseling records (ARID1A versus ARID1B subtype counseling — explicit documentation that this individual has ARID1A CSS Type 2 and not ARID1B CSS Type 1, with the cancer surveillance implication clearly stated; neurodevelopmental phenotype counseling — ID severity, behavioral features, epilepsy risk at approximately 25%, hearing risk, ophthalmology monitoring; cancer surveillance counseling for adult female carriers — ovarian cancer, endometrial cancer, and gastric cancer surveillance considerations; reproductive counseling — autosomal dominant with 50% transmission risk; de novo recurrence risk counseling; prenatal diagnosis options), and ARID1A versus ARID1B subtype documentation records (molecular subtype clearly recorded in the problem list, genetic counseling notes, and cancer surveillance coordination records — this documentation prevents cancer surveillance protocol misapplication in adult care transitions) at 1-minute intervals during laboratory hours. Alert immediately — ARID1A molecular testing platform failures during evaluation of an 8-year-old female with mild intellectual disability, autistic traits, hypoplastic fifth fingernails, coarse facial features, and hypotonia — when ARID1A loss-of-function identification confirms Coffin-Siris Syndrome Type 2, documents that this child carries a germline ARID1A pathogenic variant with future cancer surveillance implications for her adult gynecological care, initiates ABA therapy and behavioral management referrals, triggers seizure monitoring counseling, and creates the cancer surveillance flag that must transfer with this individual into adult healthcare.
Cancer Surveillance Coordination Records
Monitor gynecological cancer surveillance records (adult female ARID1A germline pathogenic variant carrier surveillance records — gynecological oncology consultation scheduling; ovarian cancer surveillance records — transvaginal ultrasound scheduling where surveillance is indicated; CA-125 monitoring records where surveillance is indicated; endometrial cancer surveillance records — endometrial biopsy or ultrasound records where indicated; surveillance interval documentation — annual gynecological oncology review; cancer family history documentation — first-degree relatives with ovarian, endometrial, or uterine cancer), gastric cancer surveillance considerations (gastric cancer family history documentation; upper endoscopy records where gastric cancer family history or symptoms are present; Helicobacter pylori testing records; gastric cancer surveillance interval records where surveillance is indicated), cancer surveillance protocol and transition records (transition from pediatric to adult care — explicit cancer surveillance protocol transfer records; adult primary care and gynecological oncology coordination records; cancer surveillance start age documentation — consensus guidance varies and the platform must document the surveillance initiation plan; cancer screening participation records; cancer diagnosis records if malignancy develops), and ARID1A versus ARID1B cancer surveillance protocol distinction records (clear documentation that this individual requires ARID1A-specific cancer surveillance and not standard ARID1B Coffin-Siris syndrome care — the cancer surveillance differentiation is the primary platform-level distinction between the two subtypes) at 1-minute intervals during clinical hours. Alert immediately — cancer surveillance coordination platform failures preventing the gynecological oncologist from accessing the ARID1A germline variant documentation and family cancer history records during a surveillance consultation for a 28-year-old ARID1A CSS Type 2 female — when the molecular records confirming germline ARID1A loss-of-function, the family history documentation noting her maternal aunt's ovarian clear cell carcinoma diagnosis at age 42, and the surveillance protocol records specifying annual transvaginal ultrasound and CA-125 monitoring provide the genetic and family context that confirms this individual's heightened cancer surveillance requirements and directs the gynecological oncology monitoring plan.
Behavioral Management Records
Monitor ABA therapy and autism support records (ABA therapy session scheduling and data; autism spectrum diagnosis records; autism support plan documentation — functional behavior assessment, behavior intervention plan, skill acquisition program; school-based autism support records; parent-implemented behavioral intervention training records; social skills intervention records; adaptive behavior skill development tracking — communication, daily living, socialization), ADHD management records (ADHD assessment records — DSM-5-based diagnosis, behavioral rating scales; stimulant or non-stimulant medication prescription and monitoring; dose adjustment records; behavioral response at school — teacher rating scale; blood pressure and growth monitoring on stimulant medication; ADHD accommodation records — 504 plan or IEP), anxiety management records (anxiety assessment records; cognitive behavioral therapy scheduling and records; anxiety medication prescription and monitoring where pharmacological treatment is indicated; school anxiety accommodation records; behavioral avoidance documentation; separation anxiety records in young children with ARID1A neurodevelopmental disorder), and school accommodation coordination records (IEP or 504 documentation for behavioral and cognitive needs; special education service records; behavioral aide documentation; school behavioral support team coordination records) at 1-minute intervals during clinical hours.
Seizure Diary and AED Monitoring Records
Monitor seizure diary records (seizure type documentation — focal onset, generalized, myoclonic; seizure frequency and duration records; seizure precipitant documentation; post-ictal period records; seizure first aid protocol documentation for caregivers; rescue medication prescription and administration records), AED monitoring records (anti-epileptic drug prescription — AED name, dose, schedule; AED adherence documentation; AED blood level monitoring; liver function, CBC, and metabolic monitoring for AEDs requiring laboratory surveillance; AED side effect documentation including cognitive effects, weight effects, and mood effects; neurology encounter scheduling and records), and school seizure management records (school seizure action plan; 504 plan seizure accommodation records; school nurse training records; rescue medication administration authorization at school) at 1-minute intervals during clinical hours. Alert immediately — seizure diary platform failures preventing the neurologist from accessing seizure frequency and AED monitoring data during a management call for a 12-year-old ARID1A female who has had three focal seizures in the past month after two years of seizure freedom — when the seizure diary documenting that all three breakthrough seizures followed febrile illnesses, the AED blood level showing a current subtherapeutic level, and the AED adherence log revealing adherence difficulties during illness periods inform the fever-related AED protocol guidance and adherence strategy modification that this call must address.
Special Education and IEP Coordination Records
Monitor cognitive assessment records (IQ testing — mild to moderate intellectual disability range; cognitive profile documentation; adaptive behavior assessment records; neuropsychological testing records; transition planning records for adolescents; vocational and independent living skill assessment), educational support records (IEP documentation; special education service placement; cognitive, adaptive, and academic goal documentation; related service records — SLP, OT, PT; extended school year records), and multi-disciplinary coordination records (neurodevelopmental team encounter records; multi-disciplinary IEP meeting coordination; special education teacher, psychologist, and therapist coordination records) at 1-minute intervals during clinical hours.
Fifth Nail Documentation and Physical Examination Records
Monitor fifth nail documentation records (photographic documentation of fifth fingernail and toenail at diagnosis; serial photographs documenting nail hypoplasia progression or stability; podiatry referral records for nail infections or nail care difficulties; nail care documentation for caregivers), and physical examination feature documentation (coarse facial feature documentation; growth parameter records — height, weight, head circumference; short stature documentation; hypotonia assessment records in infancy and early childhood) at 1-minute intervals during clinical hours.
Hearing and Ophthalmological Monitoring Records
Monitor hearing assessment records (annual audiological assessment scheduling; pure tone audiogram records; middle ear assessment records — tympanometry; hearing loss documentation where present — type, degree, laterality; hearing aid fitting records where indicated; FM system or classroom amplification records for school), ophthalmological assessment records (annual eye examination scheduling; strabismus assessment and treatment records — patching, surgery; visual acuity records; refractive error assessment; spectacle prescription records; amblyopia monitoring records; corneal and anterior segment examination records), and growth and nutritional monitoring records (height and weight tracking on growth chart; short stature documentation — height Z-score; growth hormone evaluation records where short stature is significant; feeding therapy records where hypotonia produces feeding difficulties; nutritional assessment records) at 1-minute intervals during clinical hours.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. ARID1A neurodevelopmental disorder management coordinates across molecular genetics, oncology, developmental pediatrics, neurology, behavioral health, special education, audiology, and ophthalmology — authentication failures block the multi-specialty team at encounters where cancer surveillance records, behavioral management data, AED monitoring documentation, and molecular subtype confirmation must all be accessible simultaneously.
SSL Certificates
Monitor SSL certificate expiry across all molecular testing platforms, cancer surveillance coordination systems, behavioral management tools, AED monitoring systems, special education platforms, audiology scheduling systems, and ophthalmology coordination portals. Certificate errors disrupting cancer surveillance coordination platforms during a gynecological oncology consultation create direct patient safety risk for an adult ARID1A female in the surveillance program.
HIPAA and Rare Disease Privacy Considerations for ARID1A Neurodevelopmental Disorder
ARID1A neurodevelopmental disorder technology platforms handle molecular genetic records (ARID1A pathogenic variant, subtype documentation, de novo origin, reproductive risk counseling), cancer surveillance records (gynecological oncology monitoring, cancer diagnosis records if applicable), behavioral health records (autism diagnosis, ABA therapy, ADHD medication, anxiety treatment), seizure and AED records, special education records (IEP, cognitive testing, adaptive behavior), audiology records (hearing loss documentation), ophthalmological records (strabismus, surgical records), and intellectual disability support records across the ARID1A neurodevelopmental disorder lifespan.
Alerting Strategy for ARID1A Neurodevelopmental Disorder Tech Platforms
Immediate laboratory-hours alerting for molecular genetic testing platforms: ARID1A pathogenic variant identification and subtype documentation — the diagnosis initiating behavioral management, seizure monitoring, and cancer surveillance planning.
Immediate clinical-hours alerting for cancer surveillance coordination platforms: Gynecological oncology scheduling, ovarian and endometrial surveillance records, and ARID1A versus ARID1B subtype documentation — the adult surveillance imperative that distinguishes ARID1A from ARID1B Coffin-Siris Syndrome.
Immediate clinical-hours alerting for behavioral management platforms: ABA therapy records, ADHD medication monitoring, anxiety treatment documentation, and school accommodation records — integrated behavioral management requirements.
Immediate clinical-hours alerting for seizure diary and AED monitoring platforms: Seizure documentation, AED adherence records, and seizure action plans — epilepsy management for the 25% of affected individuals with epilepsy.
Immediate clinical-hours alerting for special education and IEP coordination platforms: Cognitive testing, adaptive behavior assessment, and educational support records.
Sustained-failure alert (10–15 minutes): Hearing assessment scheduling, ophthalmology coordination, and growth monitoring records.
30-day advance warning: SSL certificates across all platforms.
Status Page for ARID1A Neurodevelopmental Disorder Care Team Communication
A real-time status page gives molecular genetics laboratories, gynecological oncologists, developmental pediatricians, neurologists, behavioral health providers, special education coordinators, audiologists, ophthalmologists, genetic counselors, and adult care transition teams immediate platform visibility without requiring inbound IT support contact.
Vigilmon Setup for ARID1A Neurodevelopmental Disorder Tech Platforms
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | ARID1A molecular testing and subtype documentation | 1 min | Slack + PagerDuty (lab hours) | | ARID1A vs. ARID1B distinction records | 1 min | Slack + PagerDuty (lab hours) | | Cancer surveillance coordination and gynecological oncology | 1 min | Slack + PagerDuty (clinical hours) | | Ovarian and endometrial surveillance scheduling | 1 min | Slack + PagerDuty (clinical hours) | | Behavioral management: ABA, ADHD, and anxiety records | 1 min | Slack + PagerDuty (clinical hours) | | Seizure diary and AED monitoring records | 1 min | Slack + PagerDuty (clinical hours) | | Special education and IEP coordination records | 1 min | Slack + PagerDuty (clinical hours) | | Cognitive testing and adaptive behavior assessment | 1 min | Slack + PagerDuty (clinical hours) | | Annual hearing assessment scheduling and records | 2 min | Slack (business hours) | | Annual ophthalmology scheduling and strabismus records | 2 min | Slack (business hours) | | Growth monitoring and nutritional assessment | 2 min | Slack (business hours) | | Fifth nail documentation and podiatry records | 2 min | Slack (business hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure ARID1A molecular testing platforms with immediate laboratory-hours alerting — ARID1A versus ARID1B subtype documentation is the most critical record for adult cancer surveillance triage
- Add ARID1A versus ARID1B distinction records with immediate laboratory-hours alerting — this distinction must transfer intact through all care transitions
- Configure cancer surveillance coordination and gynecological oncology scheduling with immediate clinical-hours alerting — adult female ARID1A carriers require ongoing gynecological cancer surveillance distinct from ARID1B CSS
- Add ovarian and endometrial surveillance scheduling records with immediate clinical-hours alerting
- Configure behavioral management records — ABA, ADHD, and anxiety — with immediate clinical-hours alerting
- Add seizure diary and AED monitoring records with immediate clinical-hours alerting — epilepsy affects approximately 25% of ARID1A individuals
- Configure special education and IEP coordination records with immediate clinical-hours alerting
- Add cognitive testing and adaptive behavior assessment with immediate clinical-hours alerting
- Configure annual hearing assessment scheduling with sustained-failure alerting during business hours
- Add annual ophthalmology scheduling and strabismus monitoring with sustained-failure alerting
- Configure growth monitoring and nutritional assessment with sustained-failure alerting
- Add fifth nail documentation and podiatry records with sustained-failure alerting
- Enable SSL certificate monitoring across all platforms
- Add the status page URL to ARID1A cancer surveillance downtime protocols, behavioral management emergency procedures, and care transition handover workflows
Conclusion
ARID1A neurodevelopmental disorder technology platforms are embedded in clinical decisions where cancer surveillance coordination platform availability during a gynecological oncology consultation — when the gynecological oncologist must access the molecular records confirming germline ARID1A pathogenic variant loss-of-function (not ARID1B), the family cancer history documenting ovarian clear cell carcinoma in a maternal aunt at age 42, and the subtype documentation confirming that this 28-year-old female requires ARID1A-specific cancer surveillance rather than standard ARID1B Coffin-Siris syndrome monitoring, to initiate the annual transvaginal ultrasound and CA-125 surveillance program that may detect ovarian cancer at a stage where intervention substantially improves survival — cannot be disrupted by platform failures that withhold the molecular subtype documentation at the consultation where the surveillance protocol is being established; where behavioral management platform availability during an ABA therapy planning session — when the behavior analyst must access the functional behavior assessment documenting the specific antecedents and maintaining consequences for the aggressive outbursts that have increased in frequency over the past month, the ADHD medication monitoring records showing that the recent stimulant dose increase preceded the behavioral escalation, and the school behavioral incident records providing the context for developing a hypothesis-driven behavior intervention plan modification — cannot be disrupted by behavioral platform failures that prevent the longitudinal documentation review required to design an evidence-based behavior intervention plan update; and where ARID1A molecular testing platform availability during diagnostic evaluation — when ARID1A loss-of-function identification confirms Coffin-Siris Syndrome Type 2, creates the cancer surveillance flag that must accompany this child through her entire healthcare trajectory into adulthood, initiates ABA therapy and behavioral management referrals for the autism spectrum traits that are a prominent feature of her clinical presentation, triggers seizure monitoring counseling given the approximately 25% epilepsy prevalence in ARID1A neurodevelopmental disorder, and provides the subtype documentation that distinguishes her surveillance requirements from those of an ARID1B Coffin-Siris patient in the same clinic — cannot be disrupted by testing platform failures that delay a diagnosis whose cancer surveillance implications extend decades beyond the childhood neurodevelopmental care period during which the diagnosis is established.
Uptime monitoring gives ARID1A neurodevelopmental disorder tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to molecular genetics laboratories, gynecological oncologists, developmental pediatricians, neurologists, behavioral health providers, special education teams, audiologists, ophthalmologists, and compliance auditors that platform operational reliability matches the cancer surveillance urgency, behavioral management requirements, and lifelong multi-domain monitoring demands of modern ARID1A Coffin-Siris Syndrome Type 2 care.
Start monitoring your ARID1A Intellectual Disability care tech platform for free at vigilmon.online — HTTP/HZ monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #ARID1A #CoffinSiris #CoffinSirisSyndrome #BAFcomplex #chromatinremodeling #SWISNFcomplex #intellectualdisability #neurodevelopmental #autistictraits #ADHD #anxiety #epilepsy #seizure #cancersurveillance #ovariancancer #endometrialcancer #gastriccancer #tumorsuppressor #strabismus #hearingloss #shortstature #fifthfingernail #HIPAA #raredisease #healthtech #digitalhealth #uptime #sre